Worldquant Millennium Advisors LLC Buys New Holdings in Boston Scientific Co. (NYSE:BSX)

Worldquant Millennium Advisors LLC acquired a new position in Boston Scientific Co. (NYSE:BSX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 107,891 shares of the medical equipment provider's stock, valued at approximately $9,041,000.

A number of other hedge funds have also bought and sold shares of BSX. Triad Wealth Partners LLC purchased a new stake in Boston Scientific during the second quarter valued at $26,000. Values First Advisors Inc. purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at about $28,000. Andra AP fonden bought a new position in shares of Boston Scientific in the 2nd quarter worth approximately $29,000. E Fund Management Hong Kong Co. Ltd. purchased a new position in shares of Boston Scientific in the third quarter worth approximately $30,000. Finally, Capital Performance Advisors LLP bought a new stake in Boston Scientific during the third quarter valued at approximately $30,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insiders Place Their Bets

In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares of the company's stock, valued at $2,660,580.24. The trade was a 19.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the firm's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the sale, the executive vice president now owns 160,467 shares of the company's stock, valued at approximately $13,639,695. This trade represents a 45.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 328,157 shares of company stock worth $27,957,676 over the last 90 days. Company insiders own 0.50% of the company's stock.

Boston Scientific Trading Down 0.5 %

Shares of NYSE:BSX traded down $0.46 on Friday, hitting $90.07. 3,302,016 shares of the company's stock were exchanged, compared to its average volume of 4,982,464. The business's 50 day simple moving average is $87.40 and its two-hundred day simple moving average is $81.30. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The stock has a market capitalization of $132.75 billion, a price-to-earnings ratio of 74.44, a price-to-earnings-growth ratio of 2.68 and a beta of 0.80. Boston Scientific Co. has a 12 month low of $54.52 and a 12 month high of $91.93.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company's revenue was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.50 earnings per share. Analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on BSX shares. Barclays upped their price target on Boston Scientific from $78.00 to $86.00 and gave the stock an "overweight" rating in a research report on Thursday, August 22nd. Canaccord Genuity Group increased their target price on shares of Boston Scientific from $88.00 to $98.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Citigroup lifted their price target on shares of Boston Scientific from $92.00 to $98.00 and gave the company a "buy" rating in a report on Thursday, October 24th. Wells Fargo & Company increased their price objective on shares of Boston Scientific from $87.00 to $98.00 and gave the stock an "overweight" rating in a research note on Thursday, October 24th. Finally, Morgan Stanley upped their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an "overweight" rating in a report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $93.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.